Pfizer Oncology Data Presentations at the American Association for Cancer Research (AACR)
Annual Meeting 2016

The embargo on most data lifted on Wednesday, March 16, at 4:30 p.m. ET unless otherwise noted.

At the American Association for Cancer Research (AACR) Annual Meeting 2016, multiple Pfizer-sponsored abstracts will be presented highlighting clinical progress for seven Pfizer Oncology assets. The presentations span multiple tumor types and mechanisms of action.¹

Palbociclib:

(Abstract LB-196) A phase I open-label fixed-sequence two-period crossover study of the effect of multiple doses of itraconazole on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers. Hoffman J. Monday, April 18. Session Type: Late-Breaking Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 12; Poster Board: 3. (Embargoed until Friday, April 15).

(Abstract LB-198) A phase I open-label fixed-sequence two-period crossover study of the effect of multiple doses of modafinil on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers. Hoffman J. Monday, April 18. Session Type: Late-Breaking Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 12; Poster Board: 5. (Embargoed until Friday, April 15).

(Abstract 2740) Mechanistic basis of Palbociclib combinatorial activity in ER+ breast cancer and non-breast indications. Dann S. Tuesday, April 19. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 2; Poster Board: 28.

(Abstract 2826) Sustained melanoma regression is achieved with continuous palbociclib and PLX4720 treatment but not with intermittent or sequential dosing. Sheppard K. Tuesday, April 19. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 6; Poster Board: 12

Early-Pipeline Assets

Gedatolisib (PF-05212384):

(Abstract 2278) Next-generation sequencing (NGS) analysis from a phase II single-agent gedatolisib study in patients with endometrial cancer. Pathan N. Monday, April 18. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 23; Poster Board: 10.

Anti-NG-HER2 ADC (PF-06804103):

(Abstract 868) Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors. Ma D. Sunday, April 17. Session Type: Oral. Presentation Time: 4:35 p.m. – 4:50 p.m. CT. Location: Room 265.
Anti-NOTCH3 ADC (PF-06650808):

(Abstract 1206) Preclinical evaluation of targeting Notch-3 in breast cancer. Hurvitz S. Monday, April 18. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 15; Poster Board: 15.

EGFR T790M (PF-06747775):

(No Abstract) Reducing proteome reactivity of irreversible EGFR T790M inhibitors. Kath J. Tuesday, April 19. Session Type: Major Symposium. Presentation Time: 11:40 a.m. – 12:05 p.m. CT. Location: Room 343.

IDO-1 (PF-06840003):

(Abstract 4863) PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors. Tumang J. Wednesday, April 20. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 22; Poster Board: 4.

PTK7 ADC (PF-06647020):

(Abstract 1220) A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions. Damelin M. Monday, April 18. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 15; Poster Board: 29.

Other Research

(Molecular characterization of breast tumor T-cell infiltration in exome datasets. Harismendy O. Sunday, April 17. Session Type: Oral. Presentation Time: 4:35 p.m. – 4:50 p.m. CT. Location: Room 243.

(Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance. Rajbjandari P. Tuesday, April 19. Session Type: Oral. Presentation Time: 4:05 p.m. – 4:20 p.m. CT. Location: New Orleans Theater A.

(Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC. Sung M. Monday, April 18. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 17; Poster Board: 11.

(Characterizing NIR dye-IL13RA2 antibody conjugates for biodistribution studies in xenograft tumor models by fluorescence molecular tomography (FMT). Gupta P. Monday, April 18. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 16; Poster Board: 13.

(ICOS signaling promotes CD4+ effector T-cell function during antitumor responses. Metzger T. Monday, April 18. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 26; Poster Board: 12.

(Characterizing the immunogenicity of gastric cancer by transcriptomic expression based immune phenotyping. Wang K. Tuesday, April 19. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 31; Poster Board: 10.
(Abstract 5279) The first ACT: an efficient data tracking and sharing tool for ADC and linker-payload development. Loganzo F. Wednesday, April 20. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 37; Poster Board: 16.

###